Lupin rises on receiving approval from USFDA for Sevelamer Carbonate for Oral Suspension

27 Dec 2021 Evaluate

Lupin is currently trading at Rs. 908.00, up by 10.85 points or 1.21% from its previous closing of Rs. 897.15 on the BSE.

The scrip opened at Rs. 913.70 and has touched a high and low of Rs. 913.70 and Rs. 900.45 respectively. So far 5336 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1267.50 on 02-Jun-2021 and a 52 week low of Rs. 854.00 on 20-Dec-2021.

Last one week high and low of the scrip stood at Rs. 925.00 and Rs. 854.00 respectively. The current market cap of the company is Rs. 40748.27 crore.

The promoters holding in the company stood at 46.83%, while Institutions and Non-Institutions held 40.41% and 12.76% respectively.

Lupin has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) Sevelamer Carbonate for Oral Suspension, 0.8 g and 2.4 g packets to market a generic equivalent of Renvela for Oral Suspension, 0.8 g and 2.4 g Packets of Genzyme. This product will be manufactured at Lupin's Goa facility in India.

Sevelamer Carbonate for Oral Suspension (RLD: Renvela for Oral Suspension) had estimated annual sales of $51.7 million in the U.S. (IQVIA MAT September 2021).

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

2069.95 26.65 (1.30%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.